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Background: FDG-PET is a validated and widely used sensitive biomarker for neu-
rodegeneration (N) in ageing and Alzheimer’s clinical syndrome as highlighted in the
β-amyloid (A)/tau (T)/N scheme (Jack et al., 2016, 2018). Early-phase Florbetapir (eAV-
45) appears as a promising proxy for FDG-PET but needs further validation. Optimiza-
tionof the timewindowandpreprocessingmethodsof eAV-45are scarce, andnoprevi-
ous study assessed the sensitivity and the reproducibility of this measure in individual
cases.
Method: We included 191 participants including young to elderly volunteers and
Alzheimer’s clinical syndrome patients, all of whomhad both FDG-PET and dual-phase
Florbetapir acquired on the same scanner, along with structural MRI and neuropsy-
chological examinations. The time window was first optimized at the vertex level by
correlationmaximizationbetweeneAV-45andFDG-PET, and correlationminimization
between eAV-45 and late AV-45 (lAV-45). Then, the six reference regions used for PET
intensity scaling were compared by computingmetrics of: (i) vertex-wise pattern over-
lap between eAV-45 andFDG-PET (derived frompatients versus controls comparisons
and correlation with cognitive scores), and (ii) machine learning classification perfor-
mance reflecting the discriminative power of both eAV-45 and FDG-PET at the indi-
vidual level.
Result: The time interval from 0 to 4 minutes gave optimal vertex-wise within- and
inter-subject correlations of both eAV-45 versus FDG-PET (maximal) and eAV-45 ver-
sus lAV-45 (minimal) (Figure1). Balancedaccuracyof patternoverlapwasgloballymax-
imalwithpons scaling (Figure2),whereas classificationperformancebetweenpatients’
subgroups and controls were similar across scaling regions for both eAV-45 and FDG-
PET (Figure 3A). Finally, classification performance was significantly superior for com-
bined early plus late AV-45 compared to FDG-PET alone (Figure 3B).
Conclusion: Results show that eAV-45 from 0 to 4 minutes with pons scaling is an
optimal surrogate of FDG-PET in ageing and Alzheimer’s clinical syndrome. This study
highlights the strong potential of optimized dual-phase AV-45, allowing to outperform
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FDG-PET discriminative power when combining both early plus late AV-45 informa-
tion obtained from a single PET-tracer injection. Interestingly, the use of dual-phase
AV-45 instead of FDG-PET plus lAV-45will reduce the radiation dose, total time, num-
ber of visits and costs.
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